We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend aristocrats with a high yield.
Dividend Aristocrats are the companies that have raised their payouts for 25 consecutive years or more. Dividends have been an important part of the overall market return for a very long time. According to a report by S&P Global, dividends have represented approximately 31% of the total return of the broader market from 1926 to February 2025, while capital appreciation has accounted for 69%.
Growing dividends consistently highlight the companies’ confidence in their firms’ prospects as market participants see this as a sign of corporate maturity and strong balance sheets. Dividend aristocrats reveal characteristics of both capital growth and dividend income, as opposed to alternative income strategies that mainly pay attention to pure yield or pure capital appreciation.
Investors are more inclined toward dividend growth stocks, and the performance of these equities has also remained stable over the years. According to a report by S&P Global, dividend aristocrats have reported higher returns with lower volatility over the long run as compared to the broader market, which eventually resulted in higher risk-adjusted returns.
In addition to dividend growth, dividend yield is also an important component of total return. The ability to increase dividends does not come at the expense of lower yields; in fact, the dividend aristocrats index has consistently delivered higher yields than its benchmark. The index had dividend yields within the range of 2.0% to 2.8% over the 28-year period, as reported by S&P Global. Moreover, the average dividend yield of the index was 2.5%, compared with a 1.8% dividend yield of the broader market.
As highlighted above, dividend aristocrats have shown lower volatility as compared to the broader market index. Their ability to provide downside protection can be seen in the upside and downside capture ratios. The S&P report highlighted that the dividend aristocrats index has outperformed the market index 66.67% of the time in down months and 43.88% of the time in up months. Notably, the index also has a lower drawdown level compared with the benchmark index. In addition, the dividend aristocrats index provided an average excess return of 0.87% in down months over the broader market. To further emphasize their low volatility, the report mentioned that the dividend aristocrats had a market beta of 0.8 between December 29, 1989, and February 28, 2025.
With the AI boom and tech stocks taking center stage, dividend stocks are somehow overlooked by the market. However, the recent market sell-off has restored their importance, as the Dividend Aristocrats Index has surged by over 2% since the start of 2025, compared with a nearly 5% decline in the broader market. The significance of these equities is much more apparent over long periods of time. According to the S&P Global report, the dividend aristocrats index outperformed its benchmark by an average of 1.59% per year between January 2000 and February 2025. This outperformance was because of the fundamental characteristics of the constituents of the index.
A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.
Our Methodology
For this article, we scanned a list of the Dividend Aristocrat index, which tracks the performance of companies that have raised their payouts for 25 consecutive years or more. From that list, we picked 15 stocks with dividend yields above 3%, as of March 29. The stocks are ranked in ascending order of their dividend yields.
At Insider Monkey, we are obsessed with hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
AbbVie Inc. (NYSE:ABBV)
Dividend Yield as of March 29: 3.2%
AbbVie Inc. (NYSE:ABBV) ranks twelfth on our list of the best dividend aristocrat stocks. The American multinational pharmaceutical company develops and brings innovative treatments to market across a wide range of healthcare sectors. Its portfolio includes treatments in immunology, eye care, oncology, and neurology. In addition, it has a strong presence in the aesthetics sector, offering cosmetic products like Juvederm and Botox for skin care and anti-aging. The stock has surged by over 14% since the start of 2025, outperforming the broader market.
AbbVie Inc. (NYSE:ABBV) reported a revenue of $15.1 billion in the fourth quarter of 2025, which showed a 5.6% growth from the same period last year. The revenue beat analysts’ expectations by $14.87 billion. The company’s net loss on a GAAP basis came in at $0.02 per share, while adjusted diluted EPS reached $2.16, slightly above the expectations of $2.13. For 2024, collective sales of Skyrizi and Rinvoq grew to $1.77 billion, up 51% on a YoY basis due to strong global demand and market expansion.
On February 13, AbbVie Inc. (NYSE:ABBV) declared a quarterly dividend of $1.64 per share, which was in line with its previous dividend. Overall, the company has been growing its payouts for 52 consecutive years. In addition, the stock offers an attractive dividend yield of 3.2%, as of March 29.
AbbVie Inc. (NYSE:ABBV) was included in 85 hedge fund portfolios at the end of Q4 2024, up from 68 in the previous quarter, as per Insider Monkey’s database. The stakes owned by these hedge funds are worth nearly $2.5 billion in total.
Overall, ABBV ranks 12th on our list of the best dividend aristocrat stocks. While we acknowledge the potential of ABBV as an investment, our conviction lies in the belief that some deeply undervalued dividend stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a deeply undervalued dividend stock that is more promising than ABBV but that trades at 10 times its earnings and grows its earnings at double digit rates annually, check out our report about the dirt cheap dividend stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
